BPC-157: The Complete Peptide Guide

Quick Reference Card

Overview / What Is BPC-157?

The Basics

BPC-157 is a small protein fragment, just 15 amino acids long, that was originally discovered in human stomach juice. Your body already produces a version of the larger protein it comes from, which plays a role in protecting and repairing the lining of your digestive tract. Researchers isolated this specific 15-amino-acid sequence because it appeared to carry much of that protective and healing ability in a compact form.

What makes BPC-157 unusual is the range of tissues it seems to affect. While most healing compounds tend to work in one specific area, BPC-157 has been studied for its effects on tendons, ligaments, muscles, bones, the gut lining, blood vessels, and even nerve tissue. It works primarily by encouraging your body to grow new blood vessels toward damaged areas (bringing oxygen and nutrients where they are needed most) and by helping cells migrate to injury sites more quickly.

BPC-157 has been used in the peptide community for over a decade, primarily for recovery from musculoskeletal injuries. More recently, interest has grown around its potential applications in gut healing, neuroprotection, and reducing the side effects of certain medications. It remains a research compound with no FDA approval, and while animal research is extensive, human clinical data is still limited to a handful of small studies.

The Science

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide with the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), derived from human gastric juice protein BPC. First characterized by Sikiric and colleagues, BPC-157 has been the subject of extensive preclinical investigation spanning gastrointestinal, musculoskeletal, cardiovascular, and neurological models [1].

The peptide is classified as a cytoprotective agent with gastroprotective, wound healing, and tissue regeneration properties. Unlike most peptides, BPC-157 demonstrates remarkable stability in human gastric juice, maintaining structural integrity for over 24 hours in acidic conditions [1]. This unusual acid resistance enables oral bioavailability for gastrointestinal applications, a characteristic that distinguishes it from the vast majority of peptide compounds.

Preclinical research spans over 100 published studies across multiple species (rats, mice, rabbits, dogs, and pigs), demonstrating tissue-healing effects across diverse injury models [4]. However, human clinical evidence remains limited to three small studies from a single clinic, totaling fewer than 30 participants combined [12][13]. Two additional clinical trials have been registered on ClinicalTrials.gov (NCT04512612, NCT05765006), and a Phase I oral safety and pharmacokinetics trial has been completed (NCT02637284).

Molecular Identity

BPC-157 is a laboratory-synthesized peptide. The specific 15-amino-acid sequence does not occur naturally in isolated form, though it was inspired by body protection compounds found in human gastric juice. The peptide is exceptionally stable in gastric acid (over 24 hours), resistant to hydrolysis and enzymatic degradation, and can be stored at room temperature in lyophilized form.

Minor variations in reported molecular weight (1,419.53 to 1,419.56 Da) across literature reflect differences in calculation methods and hydration states.

Mechanism of Action

The Basics

BPC-157 works like a repair coordinator for your body. When tissue is damaged, whether from a torn tendon, a gut lining issue, or muscle injury, your body needs to grow new blood vessels to deliver nutrients and healing cells to the damaged area. BPC-157 amplifies this process.

Think of it as turning up the volume on your body's natural healing signals. The signal was already there, but BPC-157 makes it stronger and helps it reach further. This is why people report benefits across such different areas, from joint pain to gut issues to muscle tears. The underlying mechanism is similar across tissue types: enhanced blood vessel growth and tissue repair at the site of damage.

BPC-157 also appears to have a protective quality, helping cells survive stressful conditions that might otherwise cause damage. It seems to "read" the context of what is happening in the tissue and respond accordingly. For example, when blood flow is restricted, it promotes blood vessel growth. When inflammation is excessive, it helps calm it down. When tissue needs rebuilding, it accelerates the process of laying down new structural material.

One important consideration: the same blood-vessel-growing ability that makes BPC-157 effective for healing is also the reason researchers flag a theoretical concern about long-term use. Cancerous cells can hijack blood vessel growth pathways to fuel their own expansion. No studies have shown BPC-157 causes cancer, but the overlap in pathways means caution is warranted, particularly for extended use or in individuals with a history of malignancy.

The Science

BPC-157 exerts its regenerative effects through multiple interconnected signaling pathways, with the VEGF/VEGFR2 axis serving as the primary mechanism [2].

Angiogenesis and vascular repair. BPC-157 upregulates VEGFR2 expression at both mRNA and protein levels in endothelial cells, promotes receptor internalization, and triggers downstream PI3K-Akt signaling [2]. This activates endothelial nitric oxide synthase (eNOS), increasing nitric oxide (NO) production for vasodilation and angiogenesis. A recently identified parallel pathway involves FBXO22-dependent stabilization of BACH1, providing a VEGF-independent angiogenic mechanism [6]. Cell culture research has demonstrated vascular "running," the process by which vessels grow toward areas of injury or around vascular occlusions to reestablish blood flow [8].

Nitric oxide system modulation. BPC-157 modulates the NO system bidirectionally. It upregulates NO in NO-depleted states while providing protective effects against NO overproduction [1]. Additionally, BPC-157 activates a VEGF-independent NO pathway via Src kinase phosphorylation, which releases eNOS from inhibitory caveolin-1 binding, reducing the eNOS/caveolin-1 complex by approximately 50% [2]. This dual modulation underlies the peptide's observed effects across multiple tissue types and its context-dependent behavior in different pathological states.

Growth factor modulation and cell migration. BPC-157 activates the FAK-paxillin pathway, facilitating fibroblast migration toward damaged tissue and promoting organized collagen deposition [3]. It upregulates growth hormone receptor expression in tendon fibroblasts [9], enhances EGF and NGF signaling, and induces ERK1/2 (MAPK) pathway activation for cellular repair and division [4].

Cytoprotective effects. The peptide induces heme oxygenase-1 (HO-1) and heat shock proteins, providing protection against oxidative stress [7]. It inhibits NF-kB-mediated pro-inflammatory cytokine release and maintains gut barrier integrity through tight junction protein modulation (occludin, claudins, ZO-1) [1][7].

Neurotransmitter modulation. BPC-157 modulates dopaminergic and serotonergic systems, potentially through dopamine D2 receptor interactions [5]. Regional serotonin synthesis studies in rat brain demonstrate measurable effects on neurotransmitter production [5]. This neurochemical activity likely underlies both the reported neuroprotective properties and the mood-related effects (both positive and negative) observed in community use.

Pathway Visualization

Pharmacokinetics

The Basics

Understanding how long BPC-157 stays active in your system helps explain why most protocols involve daily dosing, sometimes twice daily.

After administration, BPC-157 is absorbed relatively quickly and begins working within hours. The peptide has a short plasma half-life, meaning it clears from your bloodstream fairly fast. However, the biological effects it triggers (like signaling blood vessels to grow or cells to migrate) continue well after the peptide itself has been cleared. Think of it like pressing a button that starts a process; the button press is brief, but the process it initiates keeps running.

For gut-specific applications, oral administration is viable because BPC-157 is unusually stable in stomach acid. Most peptides would be destroyed by digestive processes, but BPC-157 survives and can act directly on the gut lining. For systemic effects (healing injuries in tendons, muscles, joints), subcutaneous injection provides more predictable absorption and higher concentrations at the target tissue, especially when administered near the injury site.

Most protocols use once or twice daily dosing to maintain consistent signaling, and many practitioners recommend taking BPC-157 on an empty stomach for optimal absorption.

The Science

Absorption and bioavailability. BPC-157 demonstrates unusual gastric stability, allowing oral bioavailability, a characteristic rare among peptides. Subcutaneous administration provides rapid systemic distribution. The peptide preferentially accumulates at sites of tissue damage through mechanisms not yet fully characterized [24].

Onset and duration. Acute cytoprotective effects may begin within minutes of administration. Tissue healing effects (angiogenesis onset, growth factor upregulation) begin within 2–6 hours. Peak tissue repair signaling occurs at 24–72 hours with sustained dosing [2][8]. Multiple dosing maintains therapeutic effect through cumulative growth factor upregulation and progressive angiogenesis.

Route considerations. The peptide demonstrates efficacy across multiple administration routes (oral, subcutaneous, intramuscular, intraperitoneal, and topical), with preclinical data showing comparable functional outcomes regardless of route in ligament healing models [29]. Oral administration produces more pronounced local GI effects, while injection provides higher systemic bioavailability and more predictable tissue distribution for musculoskeletal applications.

Pharmacokinetic parameters (estimated):

Research & Clinical Evidence

BPC-157 and Musculoskeletal Healing

The Basics

Musculoskeletal healing is BPC-157's most extensively studied application. If you have a tendon tear, ligament injury, muscle damage, or even a bone fracture, BPC-157 may help your body repair the damage faster and with better tissue quality. The peptide does this by sending more blood (carrying oxygen and nutrients) to the injury site and helping the cells responsible for repair arrive sooner and work more efficiently.

In animal studies, BPC-157 has been shown to cut healing times significantly. Rats with completely severed Achilles tendons showed superior healing with improved strength when treated with BPC-157 compared to untreated controls. In ligament studies, researchers directly cut the MCL (a knee ligament) in rats and found that BPC-157 treated animals showed less scarring, better range of motion, and more organized tissue repair across oral, injected, and topical routes of administration.

A small human study involving 12 patients with chronic knee pain found that 11 of 12 who received a single intra-articular injection of BPC-157 reported significant improvement, with 7 experiencing relief lasting over six months. While promising, this was an uncontrolled study with subjective outcome measures.

The Science

BPC-157's musculoskeletal healing properties are among the most well-documented in preclinical literature. A 2025 systematic review identified multiple animal studies demonstrating accelerated healing across tendon, ligament, muscle, and bone injury models [14]. A concurrent narrative review examined both the regenerative evidence and potential risks [11].

Tendon healing. In a rat Achilles tendon transection model, BPC-157 at 10 mcg/kg administered intraperitoneally showed significant improvement in tensile strength at day 14 compared to control [33]. The peptide promotes tendon fibroblast outgrowth and migration in a dose-dependent manner, mediated through FAK-paxillin signaling [3]. BPC-157 also upregulates growth hormone receptor expression in tendon fibroblasts, potentially amplifying the effects of endogenous growth factors [9].

Ligament healing. In a rat MCL transection model, BPC-157 demonstrated consistent functional, biomechanical, microscopic, and histological healing improvements across oral, intraperitoneal, and topical administration routes [29]. Collagen deposition was more organized in BPC-157 treated groups, with reduced inflammatory infiltrate and less contracture formation.

Muscle healing. Accelerated healing of transected quadriceps with improved histology and restored function has been demonstrated in rat models at 10 mcg/kg intraperitoneally over 28 days [28].

Bone healing. An early study demonstrated BPC-157's osteogenic effects in a rabbit segmental bone defect model, showing efficacy comparable to bone marrow and autologous cortical bone implantation [17].

Human evidence. A retrospective study of 16 patients receiving intra-articular BPC-157 for multiple types of knee pain found that 11 of 12 patients receiving BPC-157 alone reported significant subjective improvement [20]. These results are limited by small sample size, lack of control group, and reliance on subjective outcomes.

BPC-157 and Gut Health

The Basics

Gut healing is arguably BPC-157's most natural application, given that the peptide was originally discovered in stomach juice. If you are dealing with issues like inflammatory bowel conditions, a damaged gut lining, ulcers, or general digestive discomfort, BPC-157 may help by strengthening the protective barrier of your digestive tract and calming localized inflammation.

The peptide appears to work by reinforcing the "seals" between cells in your gut wall (tight junctions), which prevents substances from leaking through where they should not. It also protects the stomach lining against damage from common irritants, including NSAIDs like ibuprofen, alcohol, and other stressors. Community reports consistently describe improvements in bloating, IBS symptoms, and digestive comfort, particularly with oral administration.

The Science

BPC-157's gastroprotective effects represent some of the earliest and most consistent findings in the preclinical literature. The peptide maintains gastric mucosal integrity through multiple protective mechanisms, including cytoprotection via the NO system and enhanced mucosal healing [1][27].

Studies demonstrate comprehensive protective effects against gastric ulcers through cytoprotection and enhanced mucosal healing across multiple injury models [27]. BPC-157 counteracts NSAID-induced gastrointestinal damage, protecting against lesions caused by celecoxib and other non-steroidal anti-inflammatory agents [1]. The peptide reinforces tight junction proteins (occludin, claudins, ZO-1), supporting gut barrier integrity and mucosal restitution [7].

In a colitis and ischemia-reperfusion model, BPC-157 preserved arcade vasculature, reduced tissue ischemia, modulated NO production in a context-dependent manner, and significantly reduced oxidative stress markers (MDA) compared to controls [30]. A Phase II trial for ulcerative colitis has been referenced in the literature, with no significant side effects reported [8].

BPC-157 and Neuroprotection

The Basics

BPC-157 is being investigated for its potential to protect and repair nerve tissue. In animal studies, it has shown promise in models of spinal cord injury, traumatic brain injury, and peripheral nerve damage. Some researchers describe it as having both a healing and a protective role in the nervous system, meaning it may help damaged nerves recover while also shielding healthy nerve cells from further harm.

Community users sometimes report improved mental clarity, focus, or mood stability, though these effects are inconsistent and some individuals report the opposite (see Side Effects section for important context on dopaminergic effects).

The Science

BPC-157 demonstrates neuroprotective properties across multiple models. In a rat spinal cord compression injury model, a single intraperitoneal dose (2 mcg/kg or 200 mcg/kg) administered 10 minutes post-injury resulted in significant functional recovery, reduced vacuole formation, and decreased necrosis over a 360-day observation period [28]. Motor function scores improved significantly compared to controls, and tail spasticity normalized in treated animals while persisting in controls throughout the study.

The peptide modulates dopaminergic and serotonergic neurotransmission, with demonstrated effects on regional serotonin synthesis in the rat brain [5]. It interacts with the dopamine D2 receptor system and stabilizes GABA-glutamate balance [5]. A comprehensive review of BPC-157's CNS effects documents neuroprotective activity against multiple neurotoxic agents and in ischemic injury models [25].

BPC-157 has also demonstrated anxiolytic effects in animal behavioral tests (elevated plus-maze, light/dark tests, shock probe/burying tests) [18], though community reports suggest variable and sometimes paradoxical effects on anxiety in human use.

BPC-157 and Cardiovascular Health

The Basics

Animal research suggests BPC-157 may support heart and blood vessel health. In rats, the peptide reversed heart failure caused by the chemotherapy drug doxorubicin and protected against dangerous changes in heart rhythm caused by certain psychiatric medications. These findings come entirely from animal studies, and no human cardiovascular data exists.

The Science

BPC-157 reversed doxorubicin-induced congestive heart failure and reduced elevated big endothelin-1 plasma concentration in rat and mouse models [15]. The peptide also counteracted QTc prolongation (a potentially dangerous heart rhythm change) induced by multiple antipsychotic and gastrointestinal medications including haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rat models [41]. These cardiovascular effects are likely mediated through the eNOS/NO pathway and vascular endothelial protection [2][8].

BPC-157 and Burn/Wound Healing

The Basics

Applied as a topical cream in animal studies, BPC-157 significantly improved burn healing. Treated animals showed better skin regeneration, preserved hair follicles and sweat glands, stronger and more elastic skin, and less scarring compared to untreated burns. The peptide even overcame the healing impairment caused by corticosteroid medications.

The Science

In a mouse burn wound model, BPC-157 cream demonstrated complete restoration of normal skin architecture, including preservation of follicular structures [16]. Quantitative measurements showed improved breaking force (skin tensile strength), enhanced elasticity, reduced transepidermal water loss (better barrier function), increased capillary density, and organized collagen fiber alignment resembling healthy tissue rather than scar tissue. The peptide counteracted corticosteroid-impaired healing, maintaining efficacy even in immunosuppressed conditions [16][26].

BPC-157 and Drug Side Effect Protection

The Basics

One of the more intriguing research areas involves BPC-157's ability to protect against side effects of other medications. In animal studies, it has been shown to protect the stomach from NSAID damage (relevant for anyone who takes ibuprofen or similar drugs regularly), protect the heart from rhythm changes caused by psychiatric medications, and reduce side effects of various pharmaceutical compounds while leaving their intended effects intact.

The Science

BPC-157 counteracts NSAID-induced gastrointestinal, liver, and brain lesions in rat models [1]. It protects against QTc prolongation caused by antipsychotic and GI motility drugs [41], attenuates neuroleptic-induced catalepsy and somatosensory disturbances [43], and demonstrates protective effects against pharmaceutical hepatotoxicity and nephrotoxicity [19]. These broad cytoprotective effects may be mediated through the peptide's ability to maintain NO system homeostasis and reduce oxidative stress across multiple organ systems [1][19].

Biomarker Evidence Matrix

Scores derived from KB source evidence quality and community sentiment analysis. Only categories with sufficient data are scored. Evidence Strength reflects quality of research data (preclinical and clinical). Reported Effectiveness reflects community-reported outcomes from the Doserly Sentiment Analysis.

Benefits & Potential Effects

The Basics

BPC-157's potential benefits center on accelerating your body's natural healing processes. Based on available research and community experience, the most consistently reported positive effects include:

Injury recovery. This is the primary reason most people use BPC-157. Tendons, ligaments, and muscles that have been slow to heal or that failed to respond to physical therapy alone may respond when BPC-157 is added to a recovery protocol. Users frequently describe years-old injuries finally resolving within weeks to months.

Gut healing. For people dealing with digestive issues, whether from IBD, IBS, leaky gut, chronic bloating, or damage from long-term NSAID use, oral BPC-157 has been reported to improve symptoms. This is one of the more attributable benefits because oral BPC-157 is often used without other compounds for GI applications.

Reduced inflammation. Both research and community reports suggest BPC-157 helps calm systemic inflammation. Users describe less overall soreness, improved mobility, and reduced flare-ups during high-activity periods.

Faster workout recovery. Athletes and active individuals report shorter recovery times between sessions, less delayed-onset muscle soreness, and the ability to maintain higher training volumes without accumulating overuse injuries.

Protective effects. BPC-157 may help protect the stomach and GI tract from damage caused by NSAIDs, alcohol, and other common irritants, a meaningful benefit for anyone who relies on these substances regularly.

It is important to note that BPC-157 is not a standalone solution. Most successful community protocols involve combining BPC-157 with appropriate physical therapy, nutrition, sleep optimization, and sometimes other complementary compounds. The peptide appears to accelerate healing that is already occurring, rather than replacing the need for proper rehabilitation.

The Science

The primary therapeutic effects of BPC-157, supported by preclinical evidence, include:

Accelerated tissue repair. Enhanced healing of tendons, ligaments, muscles, bones, and skin through VEGFR2-mediated angiogenesis, FAK-paxillin-driven fibroblast migration, and organized collagen deposition [2][3][4][8]. The peptide demonstrates efficacy exceeding that of standard angiogenic growth factors (bFGF, EGF, VEGF) in tendon healing models [8].

Gastroprotection and GI healing. Cytoprotective effects via NO system modulation, gut barrier reinforcement through tight junction protein upregulation, and protection against NSAID, alcohol, and acid-induced mucosal damage [1][7][27].

Anti-inflammatory activity. Reduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, COX-2), decreased leukocyte infiltration, and resolution of inflammatory microenvironments to favor tissue repair [1][30].

Neuroprotection. Functional recovery in spinal cord injury models, protection against neurotoxic agents, and modulation of dopaminergic/serotonergic neurotransmission [5][25][28].

Cytoprotection. Protection of multiple organ systems (heart, liver, kidney, lung) against various toxic insults, including pharmaceutical side effects, ischemia-reperfusion injury, and oxidative stress [15][19][41].

Anti-oxidant properties. Neutralization of oxidative stress markers including NO and malondialdehyde (MDA), and reduction of reactive oxygen species production in gastrointestinal tissue [30].

Side Effects & Safety Considerations

The Basics

BPC-157 has an excellent preclinical safety record. In comprehensive toxicology testing across mice, rats, rabbits, and dogs, no lethal dose was identified, and no serious adverse effects were observed even at high doses. The few small human studies that exist report good tolerability with no serious adverse events.

That said, community experience reveals a more nuanced picture. The majority of users tolerate BPC-157 without issues. However, a meaningful minority experiences side effects that range from mild to severe. Here is what the community reports:

Common and generally mild:

• Injection site redness, itching, or irritation (typical for any subcutaneous injection)
• Mild digestive changes when starting oral BPC-157 (gas, loose stools, appetite changes)
• Slight reduction in blood pressure
• Headache (infrequent)
• Dizziness (rare)

Less common but significant:

• Mood changes, including depression or emotional flatness (anhedonia); this appears to be related to BPC-157's effects on dopamine pathways
• Anxiety, sometimes severe; multiple community members have reported anxiety requiring medical attention
• Joint pain or inflammation, particularly in individuals with pre-existing autoimmune conditions
• Gynecomastia (reported in a small number of cases, possibly in individuals who are genetically predisposed)
• Fatigue, particularly after 3+ weeks of use

The anhedonia concern. The most widely discussed negative effect in community forums is anhedonia, a reduction in the ability to feel pleasure or emotional engagement. An organized group of approximately 70 individuals has documented overlapping symptoms including emotional flatness, depersonalization/derealization (DP/DR), stimulant blunting (caffeine, amphetamines losing effectiveness), and exercise intolerance. Common characteristics among affected individuals include a history of Cannabis or Kratom use, ADHD, allergies, or mast cell activation syndrome (MCAS). The proposed mechanism involves dopaminergic downregulation, potentially compounded by excessive nitric oxide production in already-sensitized systems.

The cancer concern. BPC-157 promotes angiogenesis (blood vessel growth) through the VEGF pathway. This is the same pathway that cancerous cells can hijack to fuel their own growth. No study has shown BPC-157 causes cancer. However, the theoretical concern is that in someone with an existing (possibly undiagnosed) malignancy, BPC-157 could accelerate tumor growth by providing it with a better blood supply. One community member described an experience where a pre-existing skin cancer became unusually aggressive during BPC-157 use. Most practitioners and researchers recommend limiting BPC-157 to short courses and advise against use in individuals with a history of malignancy.

When to stop: Discontinue use and consult a healthcare provider if you experience persistent injection site reactions or signs of infection, unusual swelling or rash, severe headaches or dizziness, allergic reactions (hives, breathing difficulty), persistent or worsening digestive issues, or significant mood changes (especially worsening depression, anxiety, or emotional flatness).

The Science

Preclinical safety. A comprehensive preclinical toxicology study evaluated BPC-157 across multiple species (mice, rats, rabbits, dogs) and found the peptide well-tolerated with no minimum toxic or lethal dose identified [10]. No genetic, embryo-fetal, anaphylactic, or local toxicity was observed. Extensive animal studies across multiple species show minimal adverse effects at therapeutic doses [10][23].

Human safety data. A pilot study of intravenous BPC-157 infusion (10 mg and 20 mg on consecutive days) in 2 healthy adults reported no adverse reactions and no distinguishable differences in laboratory values or vital signs [13]. An interstitial cystitis study using 10 mg bladder wall injection in 12 women showed significant symptom improvement with no reported adverse events [12]. These studies are severely limited by sample size but provide preliminary safety signals.

Angiogenesis and oncological concern. BPC-157's upregulation of VEGFR2 and VEGF pathway components raises a theoretical concern regarding malignancy [11][13]. The distinction between therapeutic angiogenesis (controlled, temporary, repair-associated) and pathological tumor angiogenesis (persistent, chaotic, mutation-driven) is important but does not eliminate the risk in individuals with existing neoplasia. No in vivo tumor-growth or metastasis studies have been published specifically for BPC-157 [11]. Caution is recommended for individuals with active malignancy, cancer history, or significant family cancer risk.

Dopaminergic effects. BPC-157's modulation of the dopamine system [5] may explain community reports of anhedonia and stimulant blunting. The peptide has been shown to block amphetamine effects in rat models for up to 42 days, suggesting significant receptor-level changes that persist beyond the period of administration.

Contraindications (based on available data):

• Pregnancy and breastfeeding (no safety data available)
• Active malignancy or recent cancer history (theoretical concern due to angiogenic properties)
• Concurrent use with blood thinners (limited data on coagulation effects)
• Caution in individuals with mast cell disorders, MCAS, or histamine intolerance
• Caution in individuals with ADHD or significant substance use history (may predispose to dopaminergic side effects)

Interaction Compatibility

Good With

The following compounds are commonly used alongside BPC-157 with reported synergistic or compatible effects. All interactions listed are based on community use patterns and limited preclinical data, not controlled human studies.

• TB-500 — The most commonly stacked healing peptide. Complementary mechanisms: BPC-157 drives angiogenesis and fibroblast activity while TB-500 promotes cell migration through different pathways. Often used together in "Wolverine" or "GLOW" stack formulations. A pre-mixed blend is also available as BPC-157 + TB-500.
• Ipamorelin — BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts [9], potentially amplifying the tissue-repair benefits of growth hormone secretagogues.
• CJC-1295 — Similar rationale to Ipamorelin; BPC-157's upregulation of GH receptors may enhance CJC-1295's effectiveness for tissue repair.
• GHK-Cu — Different mechanisms; commonly combined in regenerative protocols for skin and tissue healing. Frequently used together in "GLOW" blend formulations.
• KPV — Often combined for gut healing applications. KPV targets gut inflammation through anti-inflammatory pathways that complement BPC-157's barrier-reinforcing effects.
• GHRP-6 — No known negative interactions. Different receptor targets.
• AOD-9604 — Different mechanisms; often combined in regenerative protocols.
• Melanotan II — No known interactions; different receptor targets.
• ARA-290 — Mentioned in community discussions for nerve pain applications alongside BPC-157.
• VIP — Listed in practitioner combination protocols.
• IGF-1 LR3 — Referenced in combination protocols for enhanced tissue repair.

Not Good With

• Active malignancy — BPC-157's angiogenic properties may accelerate tumor growth by enhancing blood vessel formation near tumors. Avoid in individuals with active cancer or recent cancer history.
• Blood thinners/anticoagulants — BPC-157's angiogenic effects and NO modulation may interact with coagulation pathways. Consult a healthcare provider if using anticoagulants.
• SSRIs — Some community reports note mood interactions when combining BPC-157 with selective serotonin reuptake inhibitors. BPC-157 modulates serotonergic pathways [5], and combined use may produce unpredictable mood effects. Discuss with a prescribing physician.
• Substances affecting dopamine — Individuals using Cannabis, Kratom, amphetamines, or other dopaminergic substances may be at higher risk of anhedonia or mood disruption when using BPC-157. The side-effect community group identifies these as potential predisposing factors.

Dosing Protocols

The Basics

BPC-157 dosing varies based on the route of administration, the severity of the issue being addressed, and individual response. Here are the commonly cited ranges from available sources. These are not recommendations; always consult a healthcare professional.

Subcutaneous injection (most common route):

• Standard: 250–500 mcg once daily
• Higher protocols: 500 mcg twice daily (morning and evening)
• Most sources suggest administering near the site of injury for localized healing when possible

Oral (primarily for GI applications):

• Standard: 500 mcg to 1 mg once or twice daily
• Higher protocols: up to 2 mg daily
• Take on an empty stomach, ideally 30 minutes before meals

General guidelines from available sources:

• Start at the lower end of the range and assess your response before increasing
• Consistency matters more than exact timing; choose a schedule you can maintain daily
• Most sources recommend an empty stomach for optimal absorption
• Cycle lengths commonly range from 4 to 12 weeks
• Rest periods of 4 or more weeks between cycles are frequently mentioned

The Science

Dosing protocols for BPC-157 are extrapolated primarily from preclinical models, with limited human pharmacokinetic data to guide clinical dosing.

Preclinical dosing. Effective doses in rodent models typically range from 10–100 mcg/kg administered intraperitoneally or orally [1][3][4]. Using the FDA's Human Equivalent Dose (HED) conversion factor for rat-to-human (Km ratio = 6/37 = 0.162), the calculated HED range is 1.6–16 mcg/kg, corresponding to approximately 112–1,120 mcg for a 70 kg adult. Applying the standard FDA 10-fold safety margin yields a conservative clinical starting dose of approximately 200–250 mcg [11].

Human dosing data. The interstitial cystitis pilot study used a single 10 mg dose injected into the bladder wall with positive outcomes and no adverse effects [12]. The IV safety pilot used 10 mg and 20 mg single infusions with no adverse reactions [13]. These acute, high-dose studies provide safety data but do not inform daily dosing protocols.

Route comparison (preclinical).

Titration and cycling. A gradual titration approach is commonly described: starting at 200 mcg daily and increasing by approximately 200 mcg every 2 weeks as tolerated, with a target maintenance range of 400–600 mcg daily. Cycling protocols vary from 4–12 weeks on with 4+ weeks off, though evidence-based cycling guidelines do not exist [14].

What to Expect

Based on available research and community reports, here is a general timeline of what users commonly describe. Individual experiences vary significantly based on the nature and severity of the condition being addressed, dosage, route of administration, and individual biology.

Injectable Route:

• Weeks 1–2: Reduced inflammation and pain at the area of concern. Some users report noticeable improvement within the first few days, particularly for acute injuries. Injection site may show mild redness that resolves quickly. Some individuals experience a temporary boost in mental clarity and general wellbeing during this initial period.
• Weeks 2–4: More pronounced healing progress. Tendon and ligament injuries begin showing measurable improvement in range of motion and pain reduction. Joint mobility may feel "cleaner" with less irritation. Workout recovery times typically improve noticeably.
• Weeks 4–8: Maximum localized healing benefits. Chronic injuries that have persisted for months or years may continue improving throughout this window. Some users describe a plateau effect where further improvement slows. Long-standing injuries may require the full 8-week cycle (or longer) to show meaningful results.
• Beyond 8 weeks: Community opinion is divided on extended use. Some practitioners support cycles up to 12–16 weeks for stubborn conditions. Others caution against extended use due to the theoretical angiogenesis concern. Assessment at the 8-week mark with a healthcare provider is commonly recommended.

Oral Route:

• Weeks 1–2: Improved digestive comfort, reduced GI irritation and bloating. Some users report calmer stomach within days. Transient digestive changes (loose stools, gas) may occur initially as the gut adjusts.
• Weeks 2–4: Enhanced gastric protection and healing. Reduction in reflux symptoms, improved regularity, less reactivity to common trigger foods.
• Weeks 4–8: Continued GI healing and potential systemic benefits. Some users report long-lasting improvements that persist even after discontinuing BPC-157.

Important context: Not everyone responds to BPC-157. Some community members report no noticeable benefit after full cycles. Others note that the peptide works better for certain types of injuries (soft tissue tears, inflammation-driven pain) than others (structural issues like disc herniations, cartilage degeneration). Response rates and timelines should be viewed as general patterns, not guarantees.

Administration Guide

BPC-157 can be administered via subcutaneous injection, oral capsule, or (less commonly) intramuscular injection or topical application. The following describes the general materials and considerations associated with each route. Always consult a healthcare professional before starting any protocol.

Materials typically associated with subcutaneous administration:

• Bacteriostatic water (BAC water) for reconstitution
• U-100 insulin syringes (29–31 gauge, 5/16" to 1/2" needle)
• Alcohol swabs (70% isopropyl)
• Sharps disposal container
• Sterile gauze pads

Reconstitution solution: Bacteriostatic water is the standard reconstitution medium. The volume of BAC water added determines the concentration per unit on the insulin syringe. Common reconstitution volumes are 2.0 mL (for a 5 mg vial, yielding 2.5 mg/mL) or 3.0 mL (yielding 1.67 mg/mL for easier unit measurement on standard syringes).

Timing considerations:

• Most sources recommend administration on an empty stomach for optimal absorption
• Morning administration is commonly suggested for once-daily protocols
• For twice-daily protocols, morning and evening dosing is typical
• For GI applications using oral BPC-157, taking 30 minutes before meals may maximize direct contact with the gut lining
• When using BPC-157 alongside other healing peptides like TB-500, different injection sites should be used for each compound

Post-administration care:

• Monitor injection sites for redness, swelling, or signs of infection
• Rotate injection sites systematically to prevent lipohypertrophy
• Do not massage the injection area after administration, as this may disrupt absorption
• Log each administration (dose, site, time, any reactions) for tracking and consistency
• The Doserly app can help track daily administration, side effects, and responses over time

Supplies & Planning

The following lists the general materials typically associated with BPC-157 protocols. Do not use this as a prescriptive supply list. Consult a healthcare provider for guidance on specific quantities and protocol details, and use the reconstitution calculator for precise preparation math.

Peptide vials. BPC-157 is commonly available in 5 mg and 10 mg vial sizes. The vial size affects reconstitution concentration and how many doses each vial provides. Multiple vials are typically needed for a full cycle.

Bacteriostatic water. Available in 10 mL bottles. Approximately 2–3 mL is used per vial for reconstitution, depending on the desired concentration. Plan for enough BAC water to reconstitute all vials in your cycle, with some margin for waste.

Insulin syringes. U-100 insulin syringes (0.5 mL or 1 mL capacity) with 29–31 gauge needles are standard. Use a new sterile syringe for each injection. For volumes under 10 units, consider using 30-unit or 50-unit syringes for improved measurement accuracy.

Alcohol swabs. Two per administration session (one for the vial stopper, one for the injection site).

Sharps container. For safe disposal of used syringes. Available at most pharmacies.

Storage containers. Consider light-protective wrapping (foil) for reconstituted vials to slow UV-accelerated degradation.

Storage & Handling

Proper storage preserves peptide potency and safety. BPC-157 is more stable than most peptides, but following best practices ensures consistent quality throughout the cycle.

Lyophilized (powder) form:

• Room temperature is acceptable for short periods (days to weeks) if the vial is sealed, dry, and protected from light
• Short-term storage: refrigerate at 2–8°C (35.6–46.4°F) for weeks to months
• Long-term storage: freeze at -20°C (-4°F) or below. Ideal for extended storage up to 2–3 years at -80°C
• Allow vials to reach room temperature before opening (10–30 minutes) to prevent condensation, which can degrade the powder
• Store in a dry, dark environment; peptides are hygroscopic and light-sensitive
• Keep in original sealed packaging with desiccant to minimize moisture exposure

Reconstituted (liquid) form:

• Refrigerate immediately at 2–8°C (35.6–46.4°F) after reconstitution
• Use within 28 days for optimal potency when using bacteriostatic water (containing 0.9% benzyl alcohol as a preservative)
• Do NOT freeze reconstituted solutions; freezing denatures peptides and causes irreversible degradation
• Avoid repeated freeze-thaw cycles, which can reduce potency by 25%+ per cycle
• Inspect before each use: solution should be colorless and clear with no cloudiness, particles, or discoloration. Discard if any anomalies are observed

Quality indicators:

• Good: white, fluffy "cake" appearance filling most of the vial bottom; crystal clear solution after reconstitution
• Acceptable: small clumps that dissolve completely with gentle swirling (shipping can cause minor compaction)
• Discard: collapsed, melted, or powder stuck to vial sides (heat exposure); persistent cloudiness, particles, or precipitates after mixing (degradation or contamination)

Handling best practices:

• Label vials with the reconstitution date
• Swab the vial stopper with alcohol before each draw; use sterile needles and syringes
• Wrap vials in foil or store in opaque containers to protect from UV light
• Avoid storing vials in the refrigerator door where temperature fluctuates
• Never store open vials; always reseal tightly

Lifestyle Factors

Complementary lifestyle practices can support the healing processes that BPC-157 targets. These factors are not specific to BPC-157 but are generally important for anyone focused on tissue recovery and overall health optimization.

Nutrition. A high-protein, nutrient-dense diet supplies the amino acids necessary for repair of tendons, ligaments, gut lining, and other tissues. Collagen-rich foods or collagen supplementation may provide additional building blocks. Adequate vitamin C supports collagen synthesis. Anti-inflammatory foods (omega-3 fatty acids, leafy greens, berries) complement BPC-157's anti-inflammatory effects.

Exercise and movement. Stay physically active with mobility-focused exercise or physical therapy to guide proper remodeling of newly formed tissues. For musculoskeletal injuries, progressive loading within pain tolerance helps the healing tissue adapt appropriately. Avoid complete immobilization (which can lead to disorganized tissue repair) and excessive loading (which can re-injure healing tissue). BPC-157 does not replace the need for rehabilitation; it may accelerate it.

Sleep. Prioritize 7–9 hours of quality sleep to facilitate the systemic release of growth factors that work synergistically with BPC-157's localized healing effects. Growth hormone, released primarily during deep sleep, plays a critical role in tissue repair.

Hydration. Maintain optimal hydration to support systemic circulation, ensuring the peptide and essential nutrients are delivered efficiently to injury sites.

Stress management. Chronic stress elevates cortisol, which can impair healing and increase inflammation. Stress reduction practices support the pro-repair environment that BPC-157 promotes.

Monitoring. Track your progress systematically. Note pain levels, range of motion, digestive symptoms, sleep quality, mood, and energy alongside your protocol details. The Doserly app enables correlation between health stack inputs (medications, supplements, peptides) and wellness outcomes over time, helping identify what is working and what may need adjustment.

Regulatory Status & Research Classification

United States (FDA)

BPC-157 is not FDA-approved for any therapeutic indication. It is classified as a research compound. The FDA has not granted it Investigational New Drug (IND) status through the standard pharmaceutical pathway. A Phase I oral safety and pharmacokinetics trial (NCT02637284) has been completed. Two additional clinical trials are registered: NCT04512612 and NCT05765006. BPC-157 is currently available through compounding pharmacies and research chemical suppliers, though the regulatory landscape for compounded peptides is evolving.

Canada (Health Canada)

BPC-157 does not hold a Drug Identification Number (DIN) or Natural Product Number (NPN). It is not classified as a Natural Health Product. Availability is limited to research contexts.

United Kingdom (MHRA)

BPC-157 is not approved by the Medicines and Healthcare products Regulatory Agency. It is classified as an unlicensed compound and is not available through standard pharmaceutical channels.

Australia (TGA)

BPC-157 is not approved by the Therapeutic Goods Administration. It has not been assigned a scheduling classification (e.g., Schedule 4 or Schedule 8). Access would require Special Access Scheme or Authorised Prescriber approval.

European Union (EMA)

BPC-157 does not hold marketing authorization from the European Medicines Agency. It is not approved for human therapeutic use in any EU member state.

WADA Status

BPC-157 is prohibited by the World Anti-Doping Agency (WADA) under category S0: Non-Approved Substances. It has been explicitly listed as a prohibited substance since 2022. No Therapeutic Use Exemption (TUE) is available for athletes. Competitive athletes should not use BPC-157 under any circumstances.

Active Clinical Trials

Regulatory status changes frequently. Always verify the current legal status of any compound in your specific country or jurisdiction before making any decisions.

FAQ

What is BPC-157?
BPC-157 is a synthetic peptide consisting of 15 amino acids, derived from a protective protein found in human stomach juice. It has been studied primarily for its tissue healing and cytoprotective properties in preclinical research. It is not FDA-approved for any therapeutic use.

Is BPC-157 safe?
Preclinical toxicology studies across multiple animal species found BPC-157 well-tolerated with no lethal dose identified. The limited human safety data (fewer than 30 participants across all studies) shows good acute tolerability. However, long-term human safety data does not exist. Community use reveals that while most individuals tolerate it well, a meaningful minority experiences side effects including mood changes, anxiety, and other adverse reactions. Consult a healthcare professional before use.

How much BPC-157 do people commonly use?
Based on available sources, the most commonly cited ranges are 250–500 mcg per day for subcutaneous injection and 500 mcg to 2 mg per day for oral administration. These ranges are extrapolated from preclinical data, and no controlled human efficacy studies have established optimal dosing. A healthcare professional can help determine what may be appropriate for individual circumstances.

Does BPC-157 work orally?
BPC-157 is uniquely stable in stomach acid, which allows it to survive the digestive process. Preclinical research demonstrates efficacy via oral administration, particularly for gastrointestinal applications. A ligament healing study in rats showed comparable functional outcomes across oral, intraperitoneal, and topical routes [29]. For systemic or localized musculoskeletal applications, injection near the injury site is more commonly discussed in community protocols.

Can BPC-157 cause cancer?
No study has demonstrated that BPC-157 causes cancer. However, the peptide promotes angiogenesis (new blood vessel growth) through the VEGF pathway, which is the same pathway that tumors can exploit to fuel their growth. The theoretical concern is that in someone with an existing malignancy, BPC-157 could provide that tumor with enhanced blood supply. Most practitioners recommend limiting use to short cycles and avoiding BPC-157 in individuals with active cancer or significant cancer history. Pre-use screening has been discussed in the community as a precautionary measure.

What about the anhedonia/mood concerns?
Community reports document cases of anhedonia (reduced ability to feel pleasure), emotional flatness, and stimulant blunting attributed to BPC-157 use. The proposed mechanism involves BPC-157's modulation of dopamine pathways, which may cause downregulation in susceptible individuals. Predisposing factors that the community has identified include history of Cannabis or Kratom use, ADHD, and mast cell activation issues. These effects appear to be dose-dependent and individual-specific. Most users do not experience mood side effects, but the risk is non-trivial. Starting at low doses and monitoring mood closely is commonly recommended. Consult a healthcare professional if mood changes occur.

How long does it take to work?
Response timelines vary significantly. For acute injuries, some users report reduced pain and inflammation within the first 1–2 weeks. Chronic or long-standing injuries may take 4–8 weeks or longer. Gut healing applications often show initial improvement within 1–2 weeks. Not everyone responds to BPC-157, and it appears to work better for inflammation-driven and soft tissue issues than for structural or degenerative conditions.

Can I stack BPC-157 with TB-500?
BPC-157 and TB-500 are the most commonly combined healing peptides, often used together in formulations marketed as "Wolverine" or "GLOW" stacks. They work through different but complementary mechanisms. However, stacking makes it difficult to determine which compound is producing which effect, and it does not allow identification of which peptide may be causing any side effects. Some practitioners recommend trying one compound alone before combining.

Is BPC-157 legal?
BPC-157 is not FDA-approved and is not a controlled substance in most jurisdictions. It is available as a research chemical and through compounding pharmacies. However, it is explicitly prohibited by WADA for competitive athletes. Regulatory status varies by country and is subject to change. Always verify current regulations in your jurisdiction.

How should BPC-157 be stored?
Lyophilized (powder) form can be stored at room temperature short-term but should be refrigerated or frozen for longer storage. After reconstitution with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Never freeze reconstituted peptide solutions. See the Storage & Handling section for detailed guidance.

Sources & References

Human Studies

[10] Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology. 2020;114:104665. Comprehensive toxicology study finding BPC-157 well-tolerated across multiple species with no lethal dose identified. DOI: 10.1016/j.yrtph.2020.104665

[12] Lee E, Walker C, Ayadi B, et al. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024;30(7):364-368. Pilot study of 12 women receiving 10 mg BPC-157 bladder wall injection showing significant symptom improvement. PMID: 39325560

[13] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025;31(5):210-213. Safety study of IV BPC-157 (10 mg and 20 mg) in 2 healthy adults with no adverse effects. PMID: 40131143

[20] Retrospective study of intra-articular BPC-157 for knee pain. 16 patients, single clinic. 11/12 BPC-157-only patients reported significant subjective improvement, with 7 experiencing relief >6 months. PMID: 34324435

Reviews and Meta-Analyses

[4] Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019;377(2):153-159. Review of BPC-157's musculoskeletal healing mechanisms and preclinical evidence. PMID: 30915550

[8] Seiwerth S, Sikiric P, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design. 2018;24(18):1972-1989. Comprehensive review comparing BPC-157 to standard angiogenic growth factors. DOI: 10.2174/1381612824666180712110447

[11] McGuire FP, Martinez R, Lenz A. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18:45-58. Balanced review examining both therapeutic potential and safety concerns. PMID: 40789979

[14] Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(3):412-420. Systematic review of BPC-157's orthopaedic applications. PMID: 40756949

[22] Whitehouse M. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant. Inflammopharmacology. 2025;33(4):1845-1853. Review of BPC-157's cytoprotective properties and GI tract effects. PMID: 40759852

[23] Jozwiak M, et al. Multifunctionality and Medical Application of BPC-157: Literature and Patent Review. Pharmaceuticals. 2025;18(2):185. Comprehensive review of biological activities, mechanisms, and therapeutic potential. DOI: 10.3390/ph18020185

[25] BPC-157 and CNS Repair. Neural Regeneration Research. 2022;17(3):482-487. Review of neuroprotective effects and CNS repair mechanisms. DOI: 10.4103/1673-5374.320969

[26] Wound Healing Review. Frontiers in Pharmacology. 2021;12:627533. Investigation of wound healing mechanisms, angiogenic properties, and therapeutic applications. DOI: 10.3389/fphar.2021.627533

Animal Studies

[1] Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-32. Foundational review of GI tract mechanisms and gastroprotective effects. DOI: 10.2174/138161211796197205

[2] Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. Demonstrated VEGFR2-mediated angiogenic mechanism. PMID: 27847966

[3] Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780. FAK-paxillin pathway activation in tendon healing. PMID: 21030672

[5] Tohyama Y, Sikirić P, Diksic M. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain. Life Sciences. 2004;76(13):1445-1459. Serotonergic pathway modulation in rat brain. PMID: 15531385

[6] Zhang J, Liu M, Ou H, et al. BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1. Cell Communication and Signaling. 2026;24(1):15. Novel VEGF-independent angiogenic pathway. PMID: 41606641

[7] Wang XY, Qu M, Duan R. Cytoprotective Mechanism of the Novel Gastric Peptide BPC157 in Gastrointestinal Tract and Cultured Enteric Neurons and Glial Cells. Neuroscience Bulletin. 2019;35(1):167-170. GI cytoprotection and enteric neuron effects. PMID: 30116973

[9] Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. Growth hormone receptor upregulation mechanism. DOI: 10.3390/molecules191119066

[15] Lovric-Bencic M, Sikiric P, et al. Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by BPC157. Journal of Pharmacological Sciences. 2004;95(1):19-26. Cardiovascular protective effects. PMID: 15153646

[16] Sikiric P, et al. Pentadecapeptide BPC 157 cream improves burn-wound healing and promotes skin regeneration. Burns. 2003;29(4):323-328. Burn wound healing with topical BPC-157. PMID: 11718984

[17] Sebecic B, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits. Bone. 1999;24(3):195-202. Bone healing effects comparable to autologous bone graft.

[18] Sikiric P, et al. Anxiolytic effect of pentadecapeptide BPC-157 in rats. Journal of Physiology (Paris). 2001;95(1-6):229-232. Anxiolytic effects in multiple behavioral models.

[19] Demirtaş H, et al. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Ischemia-Reperfusion Injury. Medicina (Kaunas). 2025;61(2):298. Multi-organ cytoprotection. PMID: 40005408

[21] Tian T, et al. Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of BPC-157. Molecules. 2023;28(19):6929. Metabolic profiling and half-life estimation. PMID: 37959764

[24] Pharmacokinetics of BPC-157 in rats and dogs. Frontiers in Pharmacology. 2022;13:1026182. Detailed PK study: IM bioavailability 14-19% (rat), 45-51% (dog), half-life <30 min. DOI: 10.3389/fphar.2022.1026182

[27] Gastric ulcer protection by BPC-157. Gut and Liver. 2020;14(5):547-560. Comprehensive gastroprotective mechanism study. DOI: 10.5009/gnl18490

[28] Spinal cord injury recovery with BPC-157. Journal of Orthopaedic Surgery and Research. 2019;14:241. Functional recovery after single-dose treatment in rat spinal cord compression model. DOI: 10.1186/s13018-019-1242-6 / PMID: 31266512

[29] MCL ligament healing across multiple administration routes. Journal of Applied Physiology. 2010. Comparable healing outcomes via oral, intraperitoneal, and topical routes in rat MCL transection model. PMID: 20225319

[30] Duzel A, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats. World Journal of Gastroenterology. 2017;23(48):8465-8488. NO system modulation in colitis and ischemia-reperfusion. PMID: 29358856

[33] Achilles tendon healing with BPC-157 in rats. Journal of Orthopaedic Research. 2003;21(6):976-983. Improved tensile strength and functional recovery. DOI: 10.1016/S0736-0266(03)00110-4

[34] Anti-nociceptive effect of BPC-157 on incisional pain in rats. Life Sciences. 2022;295:120389. Pain reduction mechanism. PMC: PMC8995671

In-Vitro Studies

[28] Muscle healing: accelerated quadriceps healing in rat model. Journal of Orthopaedic Research. 2006;24(5):1012-1020. DOI: 10.1002/jor.20089

Other

[41] Strinic D, et al. BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats. Life Sciences. 2017;186:66-79. Cardiac rhythm protection against antipsychotic drugs.

[43] Jelovac N, et al. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. European Journal of Pharmacology. 1999;379(1):19-31. Neuroleptic side effect attenuation.

Registered Clinical Trials

• NCT02637284 — PCO-02 Phase I safety and pharmacokinetics trial of oral BPC-157 (Completed)
• NCT04512612 — BPC-157 clinical trial (Registered)
• NCT05765006 — BPC-157 clinical trial (Registered)

Related Peptide Guides

Commonly stacked healing peptides:

• TB-500 — Complementary healing peptide, most commonly combined with BPC-157
• BPC-157 + TB-500 Blend — Pre-mixed blend of both healing peptides
• GHK-Cu — Tissue repair and skin health peptide

Growth hormone peptides (synergistic with BPC-157):

• Ipamorelin — Growth hormone secretagogue; BPC-157 upregulates GH receptors
• CJC-1295 — GHRH analog; enhanced by BPC-157's GH receptor effects
• Sermorelin — GHRH analog
• Tesamorelin — FDA-approved GHRH analog

Gut health and inflammation:

• KPV — Anti-inflammatory peptide, commonly combined for gut applications
• VIP — Vasoactive intestinal peptide

Nerve and neuroprotection:

• ARA-290 — Referenced for nerve pain applications
• Selank — Anxiolytic peptide (for those seeking mood support)
• Semax — Neuroprotective peptide

Related blend formulations:

• Wolverine Blend — Multi-peptide healing blend containing BPC-157
• BPC-157 + TB-500 10mg Blend — Higher concentration blend

Other peptides mentioned in this guide:

• GHRP-6 — Compatible growth hormone secretagogue
• AOD-9604 — Compatible regenerative peptide
• Melanotan II — Compatible; different receptor targets
• IGF-1 LR3 — Growth factor referenced in combination protocols